Literature DB >> 34597618

Broad immunophenotyping of the murine brain tumor microenvironment.

W H Tomaszewski1, J Waibl-Polania2, A M Miggelbrink2, M A Chakraborty3, P E Fecci4, J H Sampson4, M D Gunn5.   

Abstract

Here we present a 14-color flow cytometry panel for the evaluation of 13 myeloid and lymphoid populations within murine glioblastoma samples. Reagents, processing protocols, and downstream analyses were thoroughly validated and optimized to resolve the following populations: T cells (CD4, CD8, CD3), B cells (B220), NK cells (NK1.1), neutrophils (Ly6G), classical and non-classical monocytes (Ly6c, CD43), macrophages (F4/80, CD11b), microglia (CD45-lo, CD11b), and dendritic cells (DCs) (CD11c, MHC class II). In addition, this panel leaves Alexa Fluor 488/FITC open for the inclusion of fluorescent reporters or congenic marker staining.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Glioblastoma; Multicolor flow cytometry; Preclinical; Tumor microenvironment; Unbiased cell classification

Mesh：

Year:  2021        PMID： 34597618      PMCID： PMC8608727          DOI： 10.1016/j.jim.2021.113158

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN： 0022-1759            Impact factor:   2.303


  14 in total

1.  OMIP-032: Two multi-color immunophenotyping panels for assessing the innate and adaptive immune cells in the mouse mammary gland.

Authors:  Ashleigh Unsworth; Robin Anderson; Nicole Haynes; Kara Britt
Journal:  Cytometry A       Date:  2016-05-23       Impact factor: 4.355

2.  Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis.

Authors:  Jacob H Levine; Erin F Simonds; Sean C Bendall; Kara L Davis; El-ad D Amir; Michelle D Tadmor; Oren Litvin; Harris G Fienberg; Astraea Jager; Eli R Zunder; Rachel Finck; Amanda L Gedman; Ina Radtke; James R Downing; Dana Pe'er; Garry P Nolan
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

3.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Authors:  Roger Stupp; Sophie Taillibert; Andrew Kanner; William Read; David Steinberg; Benoit Lhermitte; Steven Toms; Ahmed Idbaih; Manmeet S. Ahluwalia; Karen Fink; Francesco Di Meco; Frank Lieberman; Jay-Jiguang Zhu; Giuseppe Stragliotto; David Tran; Steven Brem; Andreas Hottinger; Eilon D. Kirson; Gitit Lavy-Shahaf; Uri Weinberg; Chae-Yong Kim; Sun-Ha Paek; Garth Nicholas; Jordi Bruna; Hal Hirte; Michael Weller; Yoram Palti; Monika E. Hegi; Zvi Ram
Journal:  JAMA       Date:  2017-12-19       Impact factor: 56.272

4.  Lineage specification and plasticity in CD19- early B cell precursors.

Authors:  Lynn L Rumfelt; Yan Zhou; Benjamin M Rowley; Susan A Shinton; Richard R Hardy
Journal:  J Exp Med       Date:  2006-02-27       Impact factor: 14.307

5.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Authors:  Timothy F Cloughesy; Aaron Y Mochizuki; Joey R Orpilla; Willy Hugo; Alexander H Lee; Tom B Davidson; Anthony C Wang; Benjamin M Ellingson; Julie A Rytlewski; Catherine M Sanders; Eric S Kawaguchi; Lin Du; Gang Li; William H Yong; Sarah C Gaffey; Adam L Cohen; Ingo K Mellinghoff; Eudocia Q Lee; David A Reardon; Barbara J O'Brien; Nicholas A Butowski; Phioanh L Nghiemphu; Jennifer L Clarke; Isabel C Arrillaga-Romany; Howard Colman; Thomas J Kaley; John F de Groot; Linda M Liau; Patrick Y Wen; Robert M Prins
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440

6.  Revising CX3CR1 Expression on Murine Classical and Non-classical Monocytes.

Authors:  Aïda Meghraoui-Kheddar; Sandrine Barthelemy; Alexandre Boissonnas; Christophe Combadière
Journal:  Front Immunol       Date:  2020-06-03       Impact factor: 7.561

7.  A Protocol for the Comprehensive Flow Cytometric Analysis of Immune Cells in Normal and Inflamed Murine Non-Lymphoid Tissues.

Authors:  Yen-Rei A Yu; Emily G O'Koren; Danielle F Hotten; Matthew J Kan; David Kopin; Erik R Nelson; Loretta Que; Michael D Gunn
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

8.  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.

Authors:  David A Reardon; Alba A Brandes; Antonio Omuro; Paul Mulholland; Michael Lim; Antje Wick; Joachim Baehring; Manmeet S Ahluwalia; Patrick Roth; Oliver Bähr; Surasak Phuphanich; Juan Manuel Sepulveda; Paul De Souza; Solmaz Sahebjam; Michael Carleton; Kay Tatsuoka; Corina Taitt; Ricardo Zwirtes; John Sampson; Michael Weller
Journal:  JAMA Oncol       Date:  2020-07-01       Impact factor: 31.777

9.  OMIP-054: Broad Immune Phenotyping of Innate and Adaptive Leukocytes in the Brain, Spleen, and Bone Marrow of an Orthotopic Murine Glioblastoma Model by Mass Cytometry.

Authors:  Sophie A Dusoswa; Jan Verhoeff; Juan J Garcia-Vallejo
Journal:  Cytometry A       Date:  2019-01-31       Impact factor: 4.355

10.  Dissociation of solid tumor tissues with cold active protease for single-cell RNA-seq minimizes conserved collagenase-associated stress responses.

Authors:  Ciara H O'Flanagan; Kieran R Campbell; Allen W Zhang; Farhia Kabeer; Jamie L P Lim; Justina Biele; Peter Eirew; Daniel Lai; Andrew McPherson; Esther Kong; Cherie Bates; Kelly Borkowski; Matt Wiens; Brittany Hewitson; James Hopkins; Jenifer Pham; Nicholas Ceglia; Richard Moore; Andrew J Mungall; Jessica N McAlpine; Sohrab P Shah; Samuel Aparicio
Journal:  Genome Biol       Date:  2019-10-17       Impact factor: 13.583
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.